🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

505 results for “Oral” Clear

  1. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

  2. TREDIMIN 25.000 U.I. /2,5 ml soluzione orale

    Sana Biotechnology

    haematologic condition who need staminal cells transplant

    phase 2 small molecule active

    1 trial

  3. Tablets are oval, biconvex, plain and white to off white, Placebo for GSK4011499 Tablets are tablets for oral administration. Tablets are oval, biconvex, plain, and white to off white.

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  4. Tafenoquine Oral Tablet

    60 DEGREES PHARMACEUTICALS, INC.

    COVID 19 Disease

    phase 2 small molecule completed

    1 trial

  5. Teicoplanina Sandoz 200 mg polvere e solvente per soluzione iniettabile o infusione o soluzione orale

    Verona Pharma Ireland Limited

    cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection

    phase 2 small molecule active

    1 trial

  6. The min-102 placebo is supplied as an oral suspension with similar appearance to min-102 drug product. min-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose

    Minoryx Therapeutics S.L.

    Rett Syndrome

    phase 2 small molecule active

    1 trial

  7. Tizanidine (sublingual or oral)

    Teva Pharma GmbH

    Muscle Spasticity

    phase 2 small molecule completed

    1 trial

  8. Valbenazine Oral Capsule

    NEUROCRINE BIOSCIENCES INC

    Trichotillomania (Hair-Pulling Disorder)

    phase 2 small molecule active

    1 trial

  9. Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  10. Xyrem (sodium oxybate) oral solution

    Jazz Pharmaceuticals Ireland Limited

    Fibromyalgia

    phase 2 small molecule completed

    1 trial

  11. ZENGAC “500 mg Polvere per soluzione per infusione e per uso orale”, Plenvu, polvere per soluzione orale, SELG ESSE polvere per soluzione orale, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Vancomicina Mylan 500 mg polvere per soluzione per infusione

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  12. cRGD-ZW800-1

    Disc Medicine

    Oral cancer

    phase 2 small molecule active

    1 trial

  13. killed oral cholera vaccine

    International Peace Maternity and Child Health Hospital

    Cholera

    phase 2 mab completed

    1 trial

  14. megestrol acetate oral suspension + serplulimab + SOX

    The First People's Hospital of Lianyungang

    Stage III Gastric Cancer

    phase 2 small molecule active

    1 trial

  15. oral treprostinil

    United Therapeutics Europe Ltd

    PAH

    phase 2 small molecule completed

    1 trial

  16. 500 mg GLPG1837 as oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  17. A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

  18. A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

  19. A Phase 1 Open-Label Mass Balance clinical trial to Investigate the Absorption, Metabolism, and Excretion of Single Oral Administration of [14C]-TEV-56286 Following Multiple Oral Administrations of Nonlabeled TEV-56286 to Healthy Male Participants.

    Lacuna Pharma Pty Ltd

    Healthy participant

    phase 1 other active

    1 trial

  20. A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    Prelude Therapeutics Inc

    esophageal, gastric, or gastroesophageal junction adenocarcinoma, esophageal, gastric, or gastroesophageal junction squamous cell carcinoma, Non-small cell lung cancer (NSCLC), Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    phase 1 other active

    1 trial

  21. A Phase 1 open-label positron emission tomography TRIAL to assess changes in liver uptake of [68Ga]Ga-FAPI-46 following oral administration of single doses of AZD2389 to patients with advanced liver fibrosis (PECHORA)

    AstraZeneca AB

    advanced liver fibrosis

    phase 1 other active

    1 trial

  22. A Phase 1 relative bioavailability study in 14 healthy adult participants investigating the Arvisol® tablets to see whether its pharmacokinetic properties are similar to the reference drug which is a marketed oral soliton cannabidiol, named Epidiolex® CBD oral solution.

    Lacuna Pharma Pty Ltd

    Healthy volunteers

    phase 1 other active

    1 trial

  23. A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignacies with an IDH1 mutation.

    The George Institute

    AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation.

    phase 1 other active

    1 trial

  24. A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation

    The George Institute

    Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources